“Incidence of Inflammatory Bowel Disease Events in Adalimumab Clinical Trials Across Indications”. SKIN The Journal of Cutaneous Medicine, vol. 1, no. 3.1, Oct. 2017, p. s18, https://doi.org/10.25251/skin.1.supp.17.